As a landmark trial over the opioid crisis grows closer, Endo International (ENDP) agreed to a $10 million settlement with two Ohio counties that claimed the drug maker contributed to the problem by inappropriately marketing its addictive painkillers.

The trial, which is scheduled to begin in Oct. 21, will be the first to test arguments made by numerous cities, counties, Native American tribes, and still others that several drug makers and distributors fomented the crisis. Some 2,000 lawsuits have been combined in a massive litigation in a federal court in Cleveland, where a judge has been urging a settlement.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy